



The 11th NBCNS Research Meeting, November 29 – 30, 2018

Thursday November 29

10.00 – 11.30 *Registration and coffee*

11.30 – 12.30 *Lunch*

12.30 – 12.40 **Welcome**

Per Kogner and Ingrid Øra, NBCNS
Millessalen

Neuroblastoma

Chairs: John Inge Johnsen, Karolinska Institutet and Marie Arsenian Henriksson, Karolinska Institutet

12.40 – 13.25 **Neuroblastoma: a developmental twist**

Rogier Versteeg, Academic Medical Center of the University of Amsterdam

13.25 – 13.35 **Single-cell RNA sequencing of human neuroblastoma tumors**

Thale K. Olsen, Karolinska Institutet

13.35 – 13.45 **Understanding tumor heterogeneity of neuroblastoma using single cell sequencing**

Oscar C. Bedoya-Reina, Karolinska Institutet

13.45 – 13.55 **Sense-antisense lncRNA pairs encoded by locus 6p22.3 determine its neuroblastoma susceptibility via USP36-CHD7-SOX9 gene regulatory axis**

Tanmoy Mondal, University of Gothenburg

13.55 – 14.05 **6p22.3 Locus lncRNAs regulate MYCN stability to determine the neuroblastoma susceptibility**

Prasanna Kumar Juvvuna, University of Gothenburg

14.10 – 14.30 *Coffee*

Targeted therapies

Chairs: Per Kogner, Karolinska Institutet and Klas Blomgren, Karolinska Institutet

14.30 – 15.15 **Targeted therapies within the precision medicine area - crosstalk between bench and bedside**

Birgit Geoerger, Gustave Roussy

15.15 – 15.35 **Phase I/II trials in Sweden**

Ingrid Øra, HOPE Karolinska University Hospital



15.35 – 15.50 **Differentiation therapy for high-risk neuroblastoma by targeting the metabolic dependency on DHODH**
Cecilia Dyberg, Karolinska Institutet

15.50 – 16.00 **NBCNS clinical fellow**
Jakob Stenman, Karolinska University Hospital

Poster sessions and dinner

16.05 – 16.30 **Rapid fire oral presentations**
Chairs: Ingrid Øra, Lund University and Malin Wickström, Karolinska Institutet

16.30 – 17.30 **Poster viewing** part 1 (odd numbers at posters)

18.00 – 19.30 *Dinner*

19.30 – 20.30 **Poster viewing** part 2 (even numbers at posters)

20.30 – 22.30 **Poster viewing** part 3, *mingle with dessert*

Friday November 30

8.30 – 9.45 **Clinical case discussions focused on targeted therapy**
Chairs: Daniel Bexell, Lund University and Trond Flægstad, University Hospital of North Norway

9.50 – 10.30 *Coffee*

9.55 – 10.25 **Tips for young investigators** (with coffee)
Ruth Palmer, University of Gothenburg and Ola Hermanson, Karolinska Institutet
Triton

New models and oncogenes

Chairs: Fredrik Swartling, Uppsala University and Magnus Sabel, University of Gothenburg

10.30 – 11.15 **Mechanisms and models for neural cancers**
William Weiss, University of California San Francisco

11.15– 11.30 **Pluripotency and mTOR activity promote malignancy in MYCN-driven infant SHH medulloblastoma**
Matko Čančer, Uppsala University

11.30 – 11.45 **Neural stem cells derived from reprogrammed patient cells as novel models for childhood cancer**
Margareta Wilhelm, Karolinska Institutet



11.45 – 12.00 **MYC protein interactome profiling together with structural and cell biology reveals functionally distinct regions that cooperate to drive tumorigenesis**

Maria Sunnerhagen, Linköping University

12.00 – 12.15 **A selective high affinity MYC-binding compound inhibits MYC:MAX interaction and MYC-dependent tumor cell proliferation**

Lars-Gunnar Larsson, Karolinska Institutet

12.15 - 13.15 *Lunch*

New targets and tumor microenvironment

Chairs: Malin Blomstrand, University of Gothenburg and Helena Carén, University of Gothenburg

13.15 – 13.30 **Genomic Medicine Sweden - pediatric oncology update**

TBA

13.30 – 13.45 **PPM1D encoded WIP1 phosphatase is significant for cancer development and tumor progression and is a therapeutic target in neuroblastoma and medulloblastoma**

Per Kogner, Karolinska Institutet

13.45 – 14.00 **TargetTranslator: Big Data identifies non-Canonical Targets for High Risk Neuroblastoma**

Elin Almstedt, Uppsala University

14.00 – 14.15 **Radiation induced changes in the tumor microenvironment**

Tracy J. Berg, Lund University

14.15 – 14.30 **Selective inhibition of PGE2 enhances the cytotoxic effect of doxorubicin and vincristine on multicellular tumor spheroids**

Karin Larsson, Karolinska Institutet

14.30 – 15.00 Words from Barncancerfonden, poster prizes and concluding remarks

15.00 *Coffee*